Genus (LON:GNS) Issues Earnings Results

Genus (LON:GNS) released its quarterly earnings data on Thursday. The company reported GBX 110.30 earnings per share (EPS) for the quarter, Digital Look Earnings reports. Genus had a return on equity of 9.70% and a net margin of 7.07%.

Here are the key takeaways from Genus’ conference call:

• FY 2026 results were strong: adjusted profit before tax and adjusted EPS each rose 35%, while free cash flow increased to £62 million and leverage fell to 0.4x.
• Genus announced a £60 million share buyback for FY 2027 and recommended a 10% increase in the full-year dividend to 35.2 pence per share, reflecting confidence in cash generation and future growth.
• PIC delivered broad-based growth, including 52% royalty-revenue growth in China and market-share gains, while the new China joint venture is expected to support further expansion in the world’s largest porcine market.
• PRP regulatory progress continued with approvals or favorable determinations in Argentina, Canada, Uruguay, and Peru; commercialization is now beginning in selected Latin American markets, although approvals in Mexico and China remain pending.
• Management expects FY 2027 underlying adjusted profit before tax to be only moderately higher, with growth weighted toward the second half due to weak agricultural markets, North American disease pressures, lower Brazilian growth, depressed dairy conditions, and higher PRP and product-development costs.

Genus Trading Up 1.3%

Shares of GNS stock opened at GBX 2,188 on Friday. The company has a current ratio of 2.25, a quick ratio of 1.08 and a debt-to-equity ratio of 51.73. Genus has a 12-month low of GBX 1,943 and a 12-month high of GBX 3,220. The stock has a market capitalization of £1.45 billion, a P/E ratio of 30.82, a P/E/G ratio of 2.87 and a beta of 0.90. The firm’s 50 day moving average is GBX 2,222.27 and its 200 day moving average is GBX 2,375.37.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank restated a “buy” rating and issued a GBX 3,350 price target on shares of Genus in a research note on Thursday. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of GBX 3,216.67.

Trending Headlines about Genus

Here are the key news stories impacting Genus this week:

• Positive Sentiment: Genus launched a £60 million share buyback programme, signaling management’s confidence in the company’s long-term growth prospects. Buybacks can support earnings per share and provide demand for the stock. Genus Launches £60 Mln Share Buyback Programme
• Positive Sentiment: Fiscal 2026 results showed stronger pretax profit, lower leverage and improved financial resilience. The company also highlighted progress following its China joint venture, supporting the investment case. Genus boosts profits, cuts leverage and launches £60m buyback after China JV
• Positive Sentiment: Berenberg reaffirmed its buy recommendation and set a GBX 3,350 price target, implying substantial upside based on the reported trading level. Berenberg rating update
• Neutral Sentiment: Genus reported quarterly EPS of GBX 110.30, alongside a 9.70% return on equity and a 7.07% net margin. These figures demonstrate profitability, although investors remain focused on forward growth and revenue execution. Genus quarterly earnings results
• Negative Sentiment: The immediate reaction was negative because revenue missed expectations and management guided to only moderate fiscal 2027 operating-profit growth. The outlook raised concerns that near-term growth may not justify the company’s valuation. Genus Shares Fall as Company Forecasts Moderate FY27 Operating Profit Growth

Insiders Place Their Bets

In other news, insider Celia Baxter purchased 2,336 shares of the stock in a transaction dated Friday, June 26th. The shares were purchased at an average cost of GBX 2,140 per share, with a total value of £49,990.40. Corporate insiders own 0.71% of the company’s stock.

About Genus

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.